Delving into the Latest Updates on BI-0115 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

LOX-1

Action

inhibitors

Mechanism

LOX-1 inhibitors(oxidized low density lipoprotein receptor 1 inhibitors)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Atherosclerosis

Inactive Indication-

Originator Organization

Boehringer Ingelheim GmbH

Active Organization

Boehringer Ingelheim GmbH

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC15H14ClN3O

InChIKeyQTCZUCSALXBZQR-UHFFFAOYSA-N

CAS Registry4929-23-1

AbstractThe C-type lectin family member lectin-like oxidized LDL receptor-1 (LOX-1) has been object of intensive research. Its modulation may offer a broad spectrum of therapeutic interventions ranging from cardiovascular diseases to cancer. LOX-1 mediates uptake of oxLDL by vascular cells and plays an important role in the initiation of endothelial dysfunction and its progression to atherosclerosis. So far only a few compounds targeting oxLDL-LOX-1 interaction are reported with a limited level of characterization. Here we describe the identification and characterization of BI-0115, a selective small molecule inhibitor of LOX-1 that blocks cellular uptake of oxLDL. Identified by a high throughput screening campaign, biophysical analysis shows that BI-0115 binding triggers receptor inhibition by formation of dimers of the homodimeric ligand binding domain. The structure of LOX-1 bound to BI-0115 shows that inter-ligand interactions at the receptor interfaces are key to the formation of the receptor tetramer thereby blocking oxLDL binding.

100 Deals associated with BI-0115

Login to view more data